Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new skin ointment quiet psoriasis inflammation?

NCT ID NCT07780929

Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This trial tests whether an experimental ointment called XJH05 can improve symptoms of plaque psoriasis, the most common form of the skin condition. The study enrolls a small group of adults with mild-to-moderate plaque psoriasis who apply the ointment twice daily for four weeks. Researchers will measure changes in skin appearance and itching to see if the treatment is worth further study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
XJH05 ointment, a small-molecule compound applied to the skin
What this could lead to
If successful, this could point toward a new topical treatment for plaque psoriasis that works by blocking a specific inflammatory pathway, potentially offering an alternative for people with mild-to-moderate disease.
What could go wrong
This is a very early, small exploratory study with only 5 participants, so results may not apply broadly. The ointment's safety and effectiveness in humans are still unproven, and it may not outperform existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Inclusion Criteria: * Diagnosis of plaque psoriasis. * Mild-to-moderate disease presentation suitable for topical intervention (e.g., ≤2% to 10% BSA). * Provision of written informed consent prior to study procedures. 2. Exclusion Criteria: * Non-plaque subtypes (e.g., erythrodermic, pustular, or generalized guttate psoriasis). * Recent use of systemic antipsoriatic therapies, biologics, or topical steroids/retinoids within the protocol-defined washout period. * Active localized skin infection at target sites or known hypersensitivity to XJH05 or ointment ingredients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis Psoriasis (PSO)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Dermatology, Xijing Hospital, Air Force Medical University

    RECRUITING

    Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.